PT721343E - Formulacoes farmaceuticas de factor de crescimento do tecido nervoso - Google Patents

Formulacoes farmaceuticas de factor de crescimento do tecido nervoso

Info

Publication number
PT721343E
PT721343E PT94925903T PT94925903T PT721343E PT 721343 E PT721343 E PT 721343E PT 94925903 T PT94925903 T PT 94925903T PT 94925903 T PT94925903 T PT 94925903T PT 721343 E PT721343 E PT 721343E
Authority
PT
Portugal
Prior art keywords
growth factor
pharmaceutical formulations
tissue growth
nervous tissue
nerve growth
Prior art date
Application number
PT94925903T
Other languages
English (en)
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Llc filed Critical Syntex Llc
Publication of PT721343E publication Critical patent/PT721343E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT94925903T 1993-08-20 1994-08-16 Formulacoes farmaceuticas de factor de crescimento do tecido nervoso PT721343E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor

Publications (1)

Publication Number Publication Date
PT721343E true PT721343E (pt) 2003-01-31

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94925903T PT721343E (pt) 1993-08-20 1994-08-16 Formulacoes farmaceuticas de factor de crescimento do tecido nervoso

Country Status (32)

Country Link
US (2) US6277828B1 (pt)
EP (1) EP0721343B1 (pt)
JP (2) JP4592830B2 (pt)
KR (1) KR100341193B1 (pt)
CN (1) CN1163265C (pt)
AT (1) ATE226085T1 (pt)
AU (1) AU677699B2 (pt)
BG (1) BG62951B1 (pt)
BR (1) BR9407278A (pt)
CA (1) CA2169834C (pt)
CZ (1) CZ292422B6 (pt)
DE (1) DE69431562T2 (pt)
DK (1) DK0721343T3 (pt)
ES (1) ES2181723T3 (pt)
FI (1) FI113241B (pt)
HK (1) HK1012990A1 (pt)
HU (1) HU228152B1 (pt)
IL (3) IL110725A (pt)
LT (1) LT4051B (pt)
LV (1) LV11279B (pt)
NO (1) NO317627B1 (pt)
NZ (1) NZ271873A (pt)
PL (1) PL176387B1 (pt)
PT (1) PT721343E (pt)
RO (1) RO114742B1 (pt)
RU (1) RU2126265C1 (pt)
SI (1) SI9420048B (pt)
SK (1) SK284064B6 (pt)
TW (1) TW427905B (pt)
UA (1) UA43348C2 (pt)
WO (1) WO1995005845A1 (pt)
ZA (1) ZA946333B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6444201B1 (en) * 1995-05-12 2002-09-03 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
WO1997017087A1 (en) * 1995-11-07 1997-05-15 Genentech, Inc. Stabilizing formulation for ngf
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
JP2000511059A (ja) * 1996-05-29 2000-08-29 ユニバーサル プリザーベーション テクノロジーズ，インコーポレイテッド ガラス化による長期貯蔵保存
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
WO1998048832A1 (en) * 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
EP1019081A2 (en) * 1997-09-30 2000-07-19 Duke University Apolipoprotein e/growth factor complexes and methods of use
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
ATE428439T1 (de) * 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
WO2004082708A2 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
CA2534028A1 (en) * 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1703899B1 (en) * 2003-12-19 2011-05-04 Novo Nordisk Health Care AG Stabilised compositions of factor vii polypeptides
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US20090325978A1 (en) * 2006-08-14 2009-12-31 Katsumi Onai Stable lyophilized preparation
ES2407413T3 (es) * 2006-11-08 2013-06-12 P Mind Co., Ltd Aparato para acelerar la producción de factor neurotrófico
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
RU2498820C2 (ru) * 2008-09-26 2013-11-20 Адосиа Комплекс, образованный полисахаридом и нвр
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
BR112013025892B1 (pt) 2011-04-07 2021-01-19 Neovacs produto imunogênico, forma de dosagem unitária, dispositivo médico e kit relacionados a ifna
US20150005236A1 (en) * 2012-02-08 2015-01-01 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
EP3287140B1 (en) * 2015-04-21 2021-06-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
EP3287139B1 (en) * 2015-04-21 2021-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and injection powder
DK3287141T3 (da) * 2015-04-21 2021-10-11 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktorsammensætning og injektionspulver
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
KR20180123559A (ko) 2016-03-25 2018-11-16 아스텔라스세이야쿠 가부시키가이샤 PEG화 항인간 NGF 항체 Fab' 프래그먼트 함유 의약 조성물
ES2905874T3 (es) * 2016-06-01 2022-04-12 Servier Ip Uk Ltd Formulaciones de óxido de polialquileno-asparaginasa y métodos para elaborar y usar las mismas
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
IL110725A (en) 2004-09-27
CN1133012A (zh) 1996-10-09
CN1163265C (zh) 2004-08-25
LT4051B (en) 1996-10-25
CA2169834C (en) 2008-11-04
US20010007662A1 (en) 2001-07-12
BR9407278A (pt) 1996-10-01
SI9420048B (sl) 2003-12-31
ATE226085T1 (de) 2002-11-15
FI113241B (fi) 2004-03-31
NO317627B1 (no) 2004-11-29
HU228152B1 (en) 2012-12-28
US7074763B2 (en) 2006-07-11
ES2181723T3 (es) 2003-03-01
JP4592830B2 (ja) 2010-12-08
FI960750A0 (fi) 1996-02-19
FI960750A (fi) 1996-02-20
AU677699B2 (en) 1997-05-01
BG62951B1 (bg) 2000-12-29
LT96011A (en) 1996-07-25
SK18396A3 (en) 1996-10-02
LV11279B (en) 1996-10-20
LV11279A (lv) 1996-06-20
PL313084A1 (en) 1996-05-27
DE69431562T2 (de) 2003-06-18
PL176387B1 (pl) 1999-05-31
US6277828B1 (en) 2001-08-21
EP0721343B1 (en) 2002-10-16
BG100371A (bg) 1996-12-31
IL124941A (en) 2006-12-10
SI9420048A (en) 1996-10-31
JP2007314572A (ja) 2007-12-06
HU9600371D0 (en) 1996-04-29
CZ42496A3 (en) 1996-05-15
RO114742B1 (ro) 1999-07-30
HK1012990A1 (en) 1999-08-13
HUT74728A (en) 1997-02-28
RU2126265C1 (ru) 1999-02-20
IL110725A0 (en) 1994-11-11
IL124941A0 (en) 1999-01-26
JPH10508000A (ja) 1998-08-04
EP0721343A1 (en) 1996-07-17
CZ292422B6 (cs) 2003-09-17
AU7566894A (en) 1995-03-21
DK0721343T3 (da) 2003-02-17
DE69431562D1 (de) 2002-11-21
KR100341193B1 (ko) 2002-06-21
NO960651D0 (no) 1996-02-19
NZ271873A (en) 1996-10-28
CA2169834A1 (en) 1995-03-02
ZA946333B (en) 1996-02-19
WO1995005845A1 (en) 1995-03-02
NO960651L (no) 1996-02-19
UA43348C2 (uk) 2001-12-17
TW427905B (en) 2001-04-01
SK284064B6 (sk) 2004-09-08

Similar Documents

Publication Publication Date Title
PT721343E (pt) Formulacoes farmaceuticas de factor de crescimento do tecido nervoso
AU2789989A (en) Acylated uridine and cytidine and uses thereof
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
EA199900553A1 (ru) Чрескожная терапевтическая система
BR9611571A (pt) Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
CA2222698A1 (fr) Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
AU2062288A (en) Combination of pyrimidine derivatives and retinoids, as separate components, for inducing and stimulating hair growth and reducing its loss
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.
ES2062361T3 (es) Composicion cosmetica.
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
WO2000022097A3 (en) Periferal blood mensenchymal precursor cells
NO894972L (no) Polypeptidforbindelser med veksthormon-frigjoerende aktivitet.
IT8921516A0 (it) Procedimento di microincapsulazione di microorganismi vivi e composizioni farmaceutiche stabili.